Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program
Author(s)
Sheng Tzu Hung, MHA, Ya-Min Yang, MSc, PhD, MD.
Pfizer, Taipei, Taiwan.
Pfizer, Taipei, Taiwan.
OBJECTIVES: Older adults- especially those with chronic conditions like chronic obstructive pulmonary disease, coronary artery disease, and heart failure- face higher risk of severe RSV illness[1][2]. In Taiwan, the Taiwan Society of Pulmonary and Critical Care Medicine recommends vaccination for adults over 60 with underlying health conditions[3]. Based on the burden and guidance, we evaluated the clinical and economic impact of a national RSV vaccination strategy for high-risk older adults.
METHODS: Markov model was adapted to simulate the clinical and economic outcomes from the healthcare perspective over a lifetime horizon. The model compared RSV vaccination with no intervention in high-risk older adults with chronic or immunocompromising conditions. Epidemiological data from local and neighboring countries, vaccine effectiveness, utilities, and direct medical costs were sourced from scientific literature, official databases, and consultations with local experts. Both costs and utilities were discounted at an annual rate of 3%. Sensitivity and scenario analyses were conducted to explore uncertainties associated with model input parameters.
RESULTS: With all available parameters, among adults with age 60-99 with high risk, the program can avoid 3287 hospitalizations, 8641 emergency department care, and 65155 outpatient visits, also prevent 9740 deaths due to RSV infections. The analysis revealed that the additional cost of vaccine- TWD 17582M, could increase life years by 30007 and quality-adjusted life years(QALY) by 18863 compared to no vaccination. This results in an Incremental Cost-Effectiveness Ratio (ICER) of 912211 per QALY gained, falling within 3x Taiwan’s GDP per capita. One-way sensitivity analysis indicated the parameter that had the greatest impact on ICER was effectiveness of vaccine.
CONCLUSIONS: Our findings emphasize the critical importance of implementing nationwide RSV vaccination programs targeting high-risk older adults. Such initiatives have the potential to substantially reduce the clinical and economic burden of RSV infection in this population.
METHODS: Markov model was adapted to simulate the clinical and economic outcomes from the healthcare perspective over a lifetime horizon. The model compared RSV vaccination with no intervention in high-risk older adults with chronic or immunocompromising conditions. Epidemiological data from local and neighboring countries, vaccine effectiveness, utilities, and direct medical costs were sourced from scientific literature, official databases, and consultations with local experts. Both costs and utilities were discounted at an annual rate of 3%. Sensitivity and scenario analyses were conducted to explore uncertainties associated with model input parameters.
RESULTS: With all available parameters, among adults with age 60-99 with high risk, the program can avoid 3287 hospitalizations, 8641 emergency department care, and 65155 outpatient visits, also prevent 9740 deaths due to RSV infections. The analysis revealed that the additional cost of vaccine- TWD 17582M, could increase life years by 30007 and quality-adjusted life years(QALY) by 18863 compared to no vaccination. This results in an Incremental Cost-Effectiveness Ratio (ICER) of 912211 per QALY gained, falling within 3x Taiwan’s GDP per capita. One-way sensitivity analysis indicated the parameter that had the greatest impact on ICER was effectiveness of vaccine.
CONCLUSIONS: Our findings emphasize the critical importance of implementing nationwide RSV vaccination programs targeting high-risk older adults. Such initiatives have the potential to substantially reduce the clinical and economic burden of RSV infection in this population.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE230
Topic
Economic Evaluation, Health Technology Assessment
Disease
Vaccines